 In this study, 125-i-seed implantation combined with a patented was used as a therapeutic option for locally advanced lung cancer with negative driving genes. The results showed that the combination therapy had better efficacy compared to 125-i implantation alone. No serious adverse events occurred during the follow-up period. This article was authored by Yiling Feng, Bo Yang, and Xiaoping Li.